Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform

 

Basel/Zurich, Switzerland, May 23, 2017, Memo Therapeutics AG, a privately-held therapeutic antibody company today announced discovery of its first human antibodies using its proprietary huMemoMABTM antibody discovery platform.

A first series of human monoclonal antibodies against a viral antigen has been identified from a human donor-derived antibody repertoire (antibodyome) library using its huMemoMABTM antibody discovery platform.

MEMO’s CSO Christoph Esslinger commented: “This result is a first step towards MEMO’s vision to build and exploit cognate human antibodyome libraries from clinically selected donors. We will use this technology for discovery of antibodies with therapeutic potential in a broad range of disease areas.”

“MEMO has now a best in class antibody discovery platform for discovery from human donors / patients, huMemoMABTM, and immunized rabbits, rbMemoMABTM, respectively. This puts MEMO in a unique position for any antibody discovery program” CEO Armin Mäder added.

This discovery project has been started through a Swiss Government sponsored CTI program of MEMO with leading Swiss Universities. It also involves 3 non-interventional clinical study protocols in which more than 70 patients and healthy donors have already been recruited for MEMO’s future antibody repertoire library.

Learn more about huMemoMAB™.

Learn more about rbMemoMAB™.